Michael Cyprys

Sep 01, 2026

Target

$150.00

Current

$106.99

Performance

3.36%

Michael Cyprys rated HOOD as Overweight on Sep 01, 2026, setting a price target of 150. Shares have remained stable near 106.99, leaving the 150 target still in play.

MIAX

Sep 01, 2026

Target

$53.00

Current

$40.62

Performance

-3.54%

On Sep 01, 2026, MIAX was given a Equal-Weight rating by Michael Cyprys, with a target price of 53. Market indecision, reflected in sideways trading near 40.62, supported the cautious call.

SCHW

Jul 27, 2026

Target

$136.00

Current

$108.24

Performance

3.90%

SCHW received a Overweight rating from Michael Cyprys on Jul 27, 2026, aiming for 136. Price action was muted, as shares hovered around 108.24 despite the bullish outlook.

CME

Jul 23, 2026

Target

$330.00

Current

$277.77

Performance

9.22%

On Jul 23, 2026, Michael Cyprys published a Overweight outlook on CME, with a target of 330. Shares gained 9.22%, underscoring the accuracy of the bullish outlook toward 330.

HLNE

Jul 21, 2026

Target

$123.00

Current

$103.16

Performance

22.40%

Michael Cyprys on Jul 21, 2026 assigned HLNE a Equal-Weight rating, with a price target of 123. Shares outperformed expectations, climbing 22.40% despite the neutral view.

BN

Jul 21, 2026

Target

$59.00

Current

$39.71

Performance

-5.79%

On Jul 21, 2026, Michael Cyprys reaffirmed BN with a Overweight rating, targeting 59. Shares slid 5.79% despite the recommendation, highlighting downside risks.

BAM

Jul 21, 2026

Target

$56.00

Current

$49.67

Performance

6.73%

BAM was rated Equal-Weight by Michael Cyprys on Jul 21, 2026, with a price objective of 56. Despite caution, upside momentum rewarded risk-takers with gains to 49.67.

APO

Jul 21, 2026

Target

$164.00

Current

$132.29

Performance

11.73%

On Jul 21, 2026, Michael Cyprys initiated coverage on APO with a Overweight rating and target of 164. The stock’s climb of 11.73% since the call highlights the foresight in the rating.

TPG

Jul 21, 2026

Target

$54.00

Current

$52.32

Performance

22.13%

Michael Cyprys issued a Equal-Weight recommendation for TPG on Jul 21, 2026, price target set at 54. A neutral call gave way to stronger-than-expected performance, closing in on 54.

STEP

Jul 21, 2026

Target

$63.00

Current

$50.50

Performance

17.52%

On Jul 21, 2026, STEP was evaluated by Michael Cyprys, who gave a Equal-Weight rating and target of 63. Investors who stayed in despite the Hold saw upside of 17.52%.

KKR

Jul 21, 2026

Target

$147.00

Current

$106.43

Performance

9.60%

Michael Cyprys rated KKR as Overweight on Jul 21, 2026, setting a price target of 147. The call has proven timely, with shares rising 9.60% toward the price target of 147.

IVZ

Jul 17, 2026

Target

$30.00

Current

$31.72

Performance

7.05%

On Jul 17, 2026, IVZ was given a Equal-Weight rating by Michael Cyprys, with a target price of 30. The stock rallied from 31.72 to 31.72 after the Hold rating, surprising to the upside.

MKTX

Jul 10, 2026

Target

$129.00

Current

$162.83

Performance

43.01%

MKTX received a Equal-Weight rating from Michael Cyprys on Jul 10, 2026, aiming for 129. Investors saw gains of 43.01% that the cautious stance didn’t fully capture.

AMP

Jul 10, 2026

Target

$489.00

Current

$551.85

Performance

8.90%

On Jul 10, 2026, Michael Cyprys published a Underweight outlook on AMP, with a target of 489. Investors who followed the Sell rating avoided losses as the stock weakened.

GEMI

Jul 10, 2026

Target

$5.50

Current

$4.29

Performance

-0.46%

Michael Cyprys on Jul 10, 2026 assigned GEMI a Equal-Weight rating, with a price target of 5.5. The Hold stance reflected consolidation, as shares held near 4.29.

ICE

Jul 10, 2026

Target

$163.00

Current

$157.85

Performance

16.70%

On Jul 10, 2026, Michael Cyprys reaffirmed ICE with a Equal-Weight rating, targeting 163. Market strength beyond 157.85 went further than the conservative outlook suggested.

LPLA

Jul 10, 2026

Target

$387.00

Current

$355.10

Performance

12.01%

LPLA was rated Overweight by Michael Cyprys on Jul 10, 2026, with a price objective of 387. A bullish response from the market helped close the gap of 31.90 to the target.

NDAQ

Jul 10, 2026

Target

$112.00

Current

$95.72

Performance

8.67%

On Jul 10, 2026, Michael Cyprys initiated coverage on NDAQ with a Overweight rating and target of 112. The stock’s climb of 8.67% since the call highlights the foresight in the rating.

RJF

Jul 10, 2026

Target

$174.00

Current

$175.95

Performance

4.66%

Michael Cyprys issued a Equal-Weight recommendation for RJF on Jul 10, 2026, price target set at 174. The rating was appropriate for a consolidating market trading near 175.95.

TW

Jul 10, 2026

Target

$122.00

Current

$103.47

Performance

5.73%

On Jul 10, 2026, TW was evaluated by Michael Cyprys, who gave a Equal-Weight rating and target of 122. Investors who stayed in despite the Hold saw upside of 5.73%.

VIRT

Jul 10, 2026

Target

$57.00

Current

$62.69

Performance

-4.73%

Michael Cyprys rated VIRT as Underweight on Jul 10, 2026, setting a price target of 57. So far, the bearish outlook hasn’t materialized, with shares flat near 62.69.

AAMI

Jun 26, 2026

Target

$78.00

Current

$90.01

Performance

24.67%

On Jun 26, 2026, AAMI was given a Equal-Weight rating by Michael Cyprys, with a target price of 78. The stock rallied from 90.01 to 90.01 after the Hold rating, surprising to the upside.

WT

Jun 26, 2026

Target

$20.50

Current

$23.74

Performance

38.02%

WT received a Equal-Weight rating from Michael Cyprys on Jun 26, 2026, aiming for 20.5. Investors saw gains of 38.02% that the cautious stance didn’t fully capture.

VRTS

Jun 26, 2026

Target

$119.00

Current

$156.82

Performance

6.26%

On Jun 26, 2026, Michael Cyprys published a Underweight outlook on VRTS, with a target of 119. Investors who followed the Sell rating avoided losses as the stock weakened.

VCTR

Jun 26, 2026

Target

$85.00

Current

$111.37

Performance

33.49%

Michael Cyprys on Jun 26, 2026 assigned VCTR a Equal-Weight rating, with a price target of 85. Shares outperformed expectations, climbing 33.49% despite the neutral view.

TROW

Jun 26, 2026

Target

$109.00

Current

$109.38

Performance

-0.81%

On Jun 26, 2026, Michael Cyprys reaffirmed TROW with a Equal-Weight rating, targeting 109. The neutral call matched muted market action of -0.81%.

BEN

Jun 26, 2026

Target

$34.00

Current

$33.01

Performance

-0.60%

BEN was rated Equal-Weight by Michael Cyprys on Jun 26, 2026, with a price objective of 34. Flat performance suggests the Hold view was reasonable.

ARES

Apr 21, 2026

Target

$163.00

Current

$138.06

Performance

15.20%

On Apr 21, 2026, Michael Cyprys initiated coverage on ARES with a Equal-Weight rating and target of 163. The Hold stance underestimated the stock’s strength as it gained 15.20%.

CG

Apr 21, 2026

Target

$66.00

Current

$47.14

Performance

-9.50%

Michael Cyprys issued a Equal-Weight recommendation for CG on Apr 21, 2026, price target set at 66. Market action validated the conservative Hold outlook with shares at 47.14.

BX

Apr 21, 2026

Target

$184.00

Current

$136.82

Performance

6.47%

On Apr 21, 2026, BX was evaluated by Michael Cyprys, who gave a Overweight rating and target of 184. This case illustrates how a timely bullish rating can translate into tangible gains of 6.47%.

CBOE

Apr 10, 2026

Target

$273.00

Current

$294.12

Performance

-0.62%

Michael Cyprys rated CBOE as Underweight on Apr 10, 2026, setting a price target of 273. So far, the bearish outlook hasn’t materialized, with shares flat near 294.12.

BSIG

Dec 20, 2024

Target

$25.00

Current

$26.34

Performance

-2.48%

On Dec 20, 2024, BSIG was given a Underweight rating by Michael Cyprys, with a target price of 25. The stock traded sideways with only a -2.48% move, leaving the Sell case unresolved.

PX

Oct 10, 2024

Target

$12.00

Current

$7.55

Performance

-31.67%

PX received a Equal-Weight rating from Michael Cyprys on Oct 10, 2024, aiming for 12. The Hold stance proved prudent, with the market softening by 31.67%.

BRDG